Next Treatments
Back to Eczema

galvokimig

TypeInjection StagePhase 2 Latest updateDec 29, 2025Phase 2 study started

What stands out

New approach in eczema

  • Acts on both IL-17A and IL-17F, which no approved eczema treatment currently does; also targets IL-13 (like Adbry and Ebglyss)
  • Binds to IL-17A (an immune signal involved in defense against microbes and tissue protection), IL-17F (an immune signal involved in defense against microbes and tissue protection) and IL-13 (a signal molecule that plays a role in allergic inflammation)
Derived from FDA substance registry · UniProt Q16552 · UniProt Q96PD4 · UniProt P35225 ·
11 US eczema labels (Adbry, Ebglyss, Cibinqo, Eucrisa, Adquey, Dupixent, Nemluvio, Zoryve, Opzelura, Vtama, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Nov 27, 2020. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Dec 29, 2025Phase 2 trial startedA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis ClinicalTrials.gov NCT07277660
  • Jun 6, 2024Phase 1/2 trial completed · Basic-science trialA Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis ClinicalTrials.gov NCT04643457
  • Apr 23, 2024Phase 1/2 main data collected · Basic-science trialA Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis ClinicalTrials.gov NCT04643457
  • Nov 27, 2020Phase 1/2 trial started · Basic-science trialA Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis ClinicalTrials.gov NCT04643457

Sources

Trials